(3R,4R)-4-AMINO-1-[[4-[(3-METHOXYPHENYL)AMINO]PYRROLO[2,1-F][1,2,4]TRIAZIN-5-YL]METHYL]PIPERIDIN-3-OL, 95.0%, 50mg

(S)-(+)-Pyrrolidine-3-carboxylic acid hydrochloride, 97.0%, 1g

2,5-di([1,1'-Biphenyl]-4-yl)-1,3,4-oxadiazole, 98%, 1g

2-methyl-2-(2-naphthyloxy)propanoic acid, 95.0%, 250mg

D-Glucaric acid (tetrahydrate), 98%, 25g

2,4-Dinitro(trifluoromethoxy)benzene, 98.0%, 1g

tert-Butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamate, 95%, 5mg

5-chloro-2-indolinecarboxylic acid hydrochloride hydrate, 95.0%, 5g

2-(DIFLUOROMETHYL)-1H-PYRROLO[2,3-B]PYRIDINE, 95.0%, 100mg

2-(2-Bromophenoxy)-n,n-dimethylacetamide, 95%, 250mg

DBD-CO-Hz [=4-(N,N-Dimethylaminosulfonyl)-7-(N-hydrazinocarbonylmethyl-N-methyl)amino-2,1,3-benzoxadiazole] [for HPLC Labeling]>98.0%(HPLC)100mg

Formic acid, 45%, pure, 10 l, plastic packaging.

6-Fluoro-1-methylindolin-2-one, 97%, 250mg